PER
Click for more information
1.23% 8.0¢ percheron therapeutics limited

Ann: US FDA Type C Meeting for ATL1102 in DMD, page-52

  1. Baremoney
    236 Posts.
    lightbulb Created with Sketch. 59
    clock Created with Sketch.
    24/04/21
    07:43
    Post #: 52693757
    Remember Arjay in the last presentation on the 25th march mark stated "within the next 3 - 6 months the funds will be needed to start the EMA phase 2B trial" that now stands at the next 2 - 5 months, so much news is coming in the next few months. Exciting times to be involved with this company. GLTA wink.png
    ANP Price at posting: 21.0¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 12  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

BHP BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning
right-arrow Created with Sketch.
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
right-arrow Created with Sketch.
TX3 Canadian fieldwork yields multiple pegmatites for Trinex
right-arrow Created with Sketch.
FWD Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
right-arrow Created with Sketch.
OBM Ora Banda sees FY26 gold output jumping to 150Koz/pa following key approval for Sand King
right-arrow Created with Sketch.
NEWS What matters for FY25: Investment; interest rates; inflation & elections
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢ 		Change
-0.001(1.23%) 		Mkt cap ! $72.12M
Open High Low Value Volume
8.2¢ 8.2¢ 8.0¢ $63.52K 777.8K

Buyers (Bids)

No. Vol. Price($)
2 43377 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 97561 1
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.